{"id":24299,"date":"2025-05-23T13:40:58","date_gmt":"2025-05-23T06:40:58","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=24299"},"modified":"2025-05-23T13:40:58","modified_gmt":"2025-05-23T06:40:58","slug":"nona-biosciences-collaboration-partner-pfizer-announces-presentation-of-phase-1-clinical-study-design-on-mesoc2-an-msln-targeting-adc-at-the-2025-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=24299","title":{"rendered":"Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2504641\/Nona_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions<span> from &#8220;Idea to IND&#8221; (I to I<sup>TM<\/sup>), today announced that its\u00a0collaborator<\/span>, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033\/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p class=\"prntaj\">MesoC2, originally developed using Nona&#8217;s proprietary Harbour Mice<sup>\u00ae<\/sup>\u00a0and integrated ADC platforms, was licensed to Pfizer in <span class=\"xn-chron\">December 2023<\/span> under a global rights <span>agreement.\u00a0Pfizer is<\/span> currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC).<\/p>\n<p><b>Poster Presentation at the 2025 ASCO Annual Meeting<br \/><\/b><b>Title: <\/b>A phase 1 study to evaluate the safety and tolerability of the antibody\u2013drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors<br \/><b>Abstract Number: <\/b>TPS3163<br \/><b>Poster Board Number:<\/b> 475a<br \/><b>Session Title: <\/b>Poster Session \u2013 Developmental Therapeutics \u2013 Molecularly Targeted Agents and Tumor Biology<br \/><b>Session Date <span>and Time<\/span>:\u00a0<\/b><span><span class=\"xn-chron\">02 June 2025<\/span>; 1:30 PM-4:30 PM <\/span><span>(CDT)<\/span><\/p>\n<p><b>Key Highlights from the Presentation:<\/b><\/p>\n<ul type=\"disc\">\n<li>MesoC2 is an\u00a0ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (<span>TOP1i<\/span>) payload (average drug-to-antibody ratio of 8).<\/li>\n<li>MesoC2 has shown potent\u00a0antitumor efficacy\u00a0in\u00a0<i>in <\/i><i>vitro<\/i>\u00a0assays and xenograft models and an acceptable safety profile in cynomolgus monkeys.<\/li>\n<li>The Phase 1 trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06466187?term=NCT06466187&amp;rank=1\" target=\"_blank\" rel=\"nofollow\">NCT06466187<\/a>) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts.<\/li>\n<\/ul>\n<p>&#8220;We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona&#8217;s Harbour Mice<sup>\u00ae<\/sup>\u00a0and <span>integrated ADC platforms to deliver innovative cancer therapies,&#8221; said Dr. <span class=\"xn-person\">Jingsong Wang<\/span>, Chairman of Nona Biosciences. &#8220;The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology.&#8221;<\/span><\/p>\n<p>Pfizer&#8217;s presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at<a href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"nofollow\">\u00a0ClinicalTrials.gov<\/a>\u00a0(NCT06466187).<\/p>\n<p><b>About MesoC2 (HBM9033\/PF-08052666)<\/b><\/p>\n<p>MesoC2 (HBM9033\/PF-08052666)\u00a0is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully\u00a0human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice<sup>\u00ae<\/sup>\u00a0platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option.<\/p>\n<p><b>About Nona Biosciences<\/b><\/p>\n<p>Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from &#8220;Idea to IND&#8221; (I to I<sup>TM<\/sup>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice<sup>\u00ae<\/sup>\u00a0platforms and the experienced therapeutic antibody discovery team.<\/p>\n<p>Harbour Mice<sup>\u00ae<\/sup>\u00a0generates fully human\u00a0monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice<sup>\u00ae<\/sup>\u00a0and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0<a href=\"https:\/\/www.nonabio.com\/\" target=\"_blank\" rel=\"nofollow\">www.nonabio.com<\/a>.<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2504641\/Nona_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Nona Biosciences, a global biotechnology company providing integrated solutions<span> from &#8220;Idea to IND&#8221; (I to I<sup>TM<\/sup>), today announced that its\u00a0collaborator<\/span>, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033\/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p class=\"prntaj\">MesoC2, originally developed using Nona&#8217;s proprietary Harbour Mice<sup>\u00ae<\/sup>\u00a0and integrated ADC platforms, was licensed to Pfizer in <span class=\"xn-chron\">December 2023<\/span> under a global rights <span>agreement.\u00a0Pfizer is<\/span> currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC).<\/p>\n<p><b>Poster Presentation at the 2025 ASCO Annual Meeting<br \/><\/b><b>Title: <\/b>A phase 1 study to evaluate the safety and tolerability of the antibody\u2013drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors<br \/><b>Abstract Number: <\/b>TPS3163<br \/><b>Poster Board Number:<\/b> 475a<br \/><b>Session Title: <\/b>Poster Session \u2013 Developmental Therapeutics \u2013 Molecularly Targeted Agents and Tumor Biology<br \/><b>Session Date <span>and Time<\/span>:\u00a0<\/b><span><span class=\"xn-chron\">02 June 2025<\/span>; 1:30 PM-4:30 PM <\/span><span>(CDT)<\/span><\/p>\n<p><b>Key Highlights from the Presentation:<\/b><\/p>\n<ul type=\"disc\">\n<li>MesoC2 is an\u00a0ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (<span>TOP1i<\/span>) payload (average drug-to-antibody ratio of 8).<\/li>\n<li>MesoC2 has shown potent\u00a0antitumor efficacy\u00a0in\u00a0<i>in <\/i><i>vitro<\/i>\u00a0assays and xenograft models and an acceptable safety profile in cynomolgus monkeys.<\/li>\n<li>The Phase 1 trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06466187?term=NCT06466187&amp;rank=1\" target=\"_blank\" rel=\"nofollow\">NCT06466187<\/a>) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts.<\/li>\n<\/ul>\n<p>&#8220;We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona&#8217;s Harbour Mice<sup>\u00ae<\/sup>\u00a0and <span>integrated ADC platforms to deliver innovative cancer therapies,&#8221; said Dr. <span class=\"xn-person\">Jingsong Wang<\/span>, Chairman of Nona Biosciences. &#8220;The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology.&#8221;<\/span><\/p>\n<p>Pfizer&#8217;s presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at<a href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"nofollow\">\u00a0ClinicalTrials.gov<\/a>\u00a0(NCT06466187).<\/p>\n<p><b>About MesoC2 (HBM9033\/PF-08052666)<\/b><\/p>\n<p>MesoC2 (HBM9033\/PF-08052666)\u00a0is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully\u00a0human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice<sup>\u00ae<\/sup>\u00a0platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option.<\/p>\n<p><b>About Nona Biosciences<\/b><\/p>\n<p>Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from &#8220;Idea to IND&#8221; (I to I<sup>TM<\/sup>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice<sup>\u00ae<\/sup>\u00a0platforms and the experienced therapeutic antibody discovery team.<\/p>\n<p>Harbour Mice<sup>\u00ae<\/sup>\u00a0generates fully human\u00a0monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice<sup>\u00ae<\/sup>\u00a0and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0<a href=\"https:\/\/www.nonabio.com\/\" target=\"_blank\" rel=\"nofollow\">www.nonabio.com<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-24299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24299"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24299\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}